Extending use of levonorgestrel 52 mg intrauterine device to 8 years

Affiliations

¹ Department of Obstetrics and Gynecology, University of California, Davis, 4860 Y St, Ste 2500, Sacramento, CA 95817. Electronic address: mdcreinin@ucdavis.edu.
² Oregon Health & Science University, Portland, OR.

Free article

Comment

Mitchell D Creinin et al. Am J Obstet Gynecol. 2023 Jul.

Free article

. 2023 Jul;229(1):84.

doi: 10.1016/j.ajog.2023.03.011. Epub 2023 Mar 16.

¹ Department of Obstetrics and Gynecology, University of California, Davis, 4860 Y St, Ste 2500, Sacramento, CA 95817. Electronic address: mdcreinin@ucdavis.edu.
² Oregon Health & Science University, Portland, OR.

No abstract available

Comment on

Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use.
Creinin MD, Schreiber CA, Turok DK, Cwiak C, Chen BA, Olariu AI. Creinin MD, et al. Am J Obstet Gynecol. 2022 Dec;227(6):871.e1-871.e7. doi: 10.1016/j.ajog.2022.05.022. Epub 2022 May 13. Am J Obstet Gynecol. 2022. PMID: 35569516
Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial.
Jensen JT, Lukkari-Lax E, Schulze A, Wahdan Y, Serrani M, Kroll R. Jensen JT, et al. Am J Obstet Gynecol. 2022 Dec;227(6):873.e1-873.e12. doi: 10.1016/j.ajog.2022.09.007. Epub 2022 Sep 9. Am J Obstet Gynecol. 2022. PMID: 36096186
Extending the use of levonorgestrel 52 mg intrauterine devices to 8 years.
Goldberg AB. Goldberg AB. Am J Obstet Gynecol. 2023 Jul;229(1):85. doi: 10.1016/j.ajog.2023.03.015. Epub 2023 Mar 16. Am J Obstet Gynecol. 2023. PMID: 36933689 No abstract available.